Victory Capital Management Inc. Has $8.34 Million Position in Avantor, Inc. (NYSE:AVTR)

Victory Capital Management Inc. lifted its stake in shares of Avantor, Inc. (NYSE:AVTR - Free Report) by 15.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 322,469 shares of the company's stock after purchasing an additional 42,132 shares during the period. Victory Capital Management Inc.'s holdings in Avantor were worth $8,342,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Versant Capital Management Inc raised its stake in shares of Avantor by 2,003.6% during the second quarter. Versant Capital Management Inc now owns 1,157 shares of the company's stock valued at $25,000 after purchasing an additional 1,102 shares in the last quarter. Blue Trust Inc. boosted its stake in Avantor by 1,830.3% during the 2nd quarter. Blue Trust Inc. now owns 1,467 shares of the company's stock valued at $31,000 after purchasing an additional 1,391 shares in the last quarter. UMB Bank n.a. bought a new stake in shares of Avantor in the 3rd quarter worth $49,000. Nisa Investment Advisors LLC lifted its holdings in shares of Avantor by 69.6% in the third quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company's stock valued at $53,000 after buying an additional 835 shares during the period. Finally, GAMMA Investing LLC boosted its stake in Avantor by 89.9% during the third quarter. GAMMA Investing LLC now owns 2,715 shares of the company's stock valued at $70,000 after buying an additional 1,285 shares in the last quarter. Institutional investors own 95.08% of the company's stock.

Avantor Trading Up 2.1 %

AVTR traded up $0.43 during mid-day trading on Friday, reaching $20.79. The stock had a trading volume of 7,511,722 shares, compared to its average volume of 6,502,038. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. Avantor, Inc. has a 52 week low of $19.59 and a 52 week high of $28.00. The stock has a market capitalization of $14.15 billion, a P/E ratio of 45.20, a P/E/G ratio of 2.39 and a beta of 1.35. The firm's fifty day simple moving average is $23.89 and its two-hundred day simple moving average is $23.86.

Analysts Set New Price Targets

AVTR has been the topic of a number of recent research reports. Robert W. Baird decreased their target price on Avantor from $27.00 to $26.00 and set an "outperform" rating on the stock in a report on Monday, October 28th. Royal Bank of Canada restated an "outperform" rating and set a $34.00 price target on shares of Avantor in a report on Thursday, September 26th. TD Cowen raised their price objective on shares of Avantor from $28.00 to $31.00 and gave the stock a "buy" rating in a research note on Monday, July 29th. Stifel Nicolaus boosted their target price on shares of Avantor from $27.00 to $28.00 and gave the company a "buy" rating in a research note on Monday, July 29th. Finally, Wells Fargo & Company decreased their target price on Avantor from $30.00 to $28.00 and set an "overweight" rating for the company in a research report on Monday, October 28th. Three equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, Avantor has a consensus rating of "Moderate Buy" and a consensus target price of $27.57.

Insider Transactions at Avantor

In other news, CAO Steven W. Eck sold 3,525 shares of Avantor stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $25.06, for a total transaction of $88,336.50. Following the transaction, the chief accounting officer now owns 29,544 shares in the company, valued at $740,372.64. The trade was a 10.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.50% of the stock is owned by corporate insiders.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.